Oakworth Capital Inc. Boosts Stock Position in Zoetis Inc. (NYSE:ZTS)

Oakworth Capital Inc. lifted its stake in Zoetis Inc. (NYSE:ZTS) by 345.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,488 shares of the company’s stock after buying an additional 5,031 shares during the quarter. Oakworth Capital Inc.’s holdings in Zoetis were worth $1,281,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of ZTS. Enterprise Financial Services Corp grew its holdings in Zoetis by 2.3% in the first quarter. Enterprise Financial Services Corp now owns 2,446 shares of the company’s stock valued at $407,000 after purchasing an additional 55 shares during the period. CreativeOne Wealth LLC grew its holdings in Zoetis by 0.4% in the second quarter. CreativeOne Wealth LLC now owns 12,833 shares of the company’s stock valued at $2,210,000 after purchasing an additional 57 shares during the period. River Street Advisors LLC grew its holdings in Zoetis by 3.4% in the fourth quarter. River Street Advisors LLC now owns 1,757 shares of the company’s stock valued at $347,000 after purchasing an additional 58 shares during the period. Perigon Wealth Management LLC boosted its stake in shares of Zoetis by 0.3% in the fourth quarter. Perigon Wealth Management LLC now owns 23,581 shares of the company’s stock worth $4,654,000 after acquiring an additional 59 shares during the last quarter. Finally, TFC Financial Management Inc. boosted its stake in shares of Zoetis by 3.3% in the third quarter. TFC Financial Management Inc. now owns 1,918 shares of the company’s stock worth $334,000 after acquiring an additional 61 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 0.8 %

ZTS traded down $1.24 on Wednesday, hitting $151.78. 2,390,289 shares of the company were exchanged, compared to its average volume of 2,952,470. Zoetis Inc. has a twelve month low of $148.48 and a twelve month high of $201.92. The company has a market cap of $69.42 billion, a price-to-earnings ratio of 30.18, a price-to-earnings-growth ratio of 2.29 and a beta of 0.85. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32. The firm has a 50-day moving average price of $178.25 and a two-hundred day moving average price of $180.59.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). The company had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The company’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.15 earnings per share. On average, equities analysts predict that Zoetis Inc. will post 5.8 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be paid a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 1.14%. The ex-dividend date is Thursday, April 18th. Zoetis’s dividend payout ratio is presently 34.12%.

Analyst Ratings Changes

ZTS has been the topic of a number of research analyst reports. The Goldman Sachs Group lifted their price target on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Barclays lifted their price objective on Zoetis from $255.00 to $260.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 14th. Stifel Nicolaus reduced their price objective on Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $230.00 price objective on shares of Zoetis in a research report on Tuesday, December 19th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Zoetis currently has a consensus rating of “Buy” and an average price target of $221.75.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the stock in a transaction on Thursday, January 18th. The stock was sold at an average price of $191.43, for a total transaction of $176,689.89. Following the sale, the executive vice president now owns 17,569 shares in the company, valued at approximately $3,363,233.67. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold a total of 2,209 shares of company stock valued at $408,453 in the last ninety days. Insiders own 0.15% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.